Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy

Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy

IntroductionThe application of programmed cell death protein 1 (PD-1) antibodies has brought significant benefits to patients with non-small cell lung cancer (NSCLC). However, not all patients respond to PD-1 immune therapy. The aim of this study was to identify response biomarkers to predict the ef...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Cao, Yuehua Zhang, Shenghu Guo, Zheng Wu, Xiaojin Guo, Rongze Zhang, Lei Zhang, Ya Liu, Xing Li, Chunwang Yang, Dongwei He, Lu Bai, Tingting Lv, Yong Xie, Chengjing Huang, Shuang Xiao, Anyi Deng, Jiawei Li, Jiaxing Zhu, Zhenghu Jia, Zhinan Yin, Zhiyu Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
immune biomarkers
NSCLC
anti-PD-1 therapy
TIM-3
cytokines
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521708/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionThe application of programmed cell death protein 1 (PD-1) antibodies has brought significant benefits to patients with non-small cell lung cancer (NSCLC). However, not all patients respond to PD-1 immune therapy. The aim of this study was to identify response biomarkers to predict the efficacy of chemotherapy combined with anti-PD-1 therapy in NSCLC patients.MethodsThirty-two NSCLC patients receiving chemotherapy combined with anti-PD-1 therapy were recruited, and peripheral blood samples were collected before and after treatment. Flow cytometry was used to detect the proportions of circulating T-cell subsets, and cytokines in the blood serum were detected via ELISA.ResultsThe results revealed that, among the CR/PR group (CR, complete response; PR, partial response; n = 22), the proportions of CD3+TIM-3+PD-1+, CD3+CD4+TIM-3+PD-1+, and CD3+CD8+TIM-3+PD-1+, CD3+γδT+PD-1+, CD3+γδT+Vδ1+PD-1+, and CD3+γδT+Vδ2+PD-1+T cells were lower after treatment, with no significant differences found between the stable disease (SD) and progressive disease (PD) groups (n = 10). Some proinflammatory cytokines are highly expressed in patients with NSCLC.DiscussionThis study suggests that monitoring changes in immune biomarkers in the circulating cells of NSCLC patients may help differentiate CR/PR patients from SD/PD patients, providing a potential new approach for assessing the efficacy of chemotherapy combined with anti-PD-1 therapy.
ISSN:1664-3224

Similar Items